Oncology is the most competitive and most demanding therapeutic area in clinical research. Trials are complex, patient populations are often narrow and biomarker-defined, sites are oversubscribed, and competition for the same patients is fierce. Choosing a CRO with genuine oncology depth is therefore not a preference but a necessity. Here is a guide to the CROs best equipped for cancer trials and what actually separates them.
Why oncology trials are different
Several features make oncology uniquely hard. Patient recruitment is a persistent bottleneck, because eligible patients are often defined by specific biomarkers or prior lines of therapy, and many trials compete for the same small pool. Trial designs are complex, with adaptive designs, basket and umbrella studies, and dose-escalation stages that demand sophisticated operational and statistical capability. Endpoints and imaging require specialized handling, particularly response assessment. Site relationships matter enormously, since the leading cancer centers are selective and oversubscribed, and a CRO’s standing with them directly affects your enrollment. And the science moves fast, so a partner who does not genuinely understand the space will struggle to keep up.
The large CROs with deep oncology capability
The global full-service CROs all run large oncology portfolios, and their scale brings real advantages in site access, data infrastructure, and multinational execution.
- IQVIA combines enormous scale with extensive data assets that can help with site and patient identification, a genuine advantage in a field where finding eligible patients is the core problem.
- Parexel and ICON both run substantial oncology franchises with deep therapeutic expertise and global site networks.
- Fortrea and Thermo Fisher’s PPD bring broad late-phase capability and established oncology experience.
- Medpace is notable for a full-service model with strong therapeutic expertise, often favored by small and mid-sized biotechs who want senior attention rather than being a small account at a giant.
The oncology-focused specialists
For many sponsors, particularly emerging biotechs running early-phase or highly specialized cancer trials, a dedicated oncology CRO is the better fit. Specialist providers focused wholly or largely on oncology bring concentrated expertise, close relationships with cancer centers and investigators, and teams who live in the therapeutic area every day. Their advantage is depth rather than breadth: they understand the specific operational realities of dose escalation, biomarker-driven enrollment, and response assessment because that is all they do. The tradeoff is that they may lack the global footprint or the full range of services of the giants, so the choice depends on whether your trial needs deep oncology specialization or broad multinational infrastructure, and often the answer is that specialization matters more.
What actually separates a good oncology CRO
Beyond the name, a few things genuinely predict success. Site relationships and access to the cancer centers that can enroll your patients may be the single most important factor, since a trial that cannot recruit cannot succeed. Genuine therapeutic depth, meaning teams who understand your tumor type, mechanism, and endpoints rather than generic clinical operations staff, changes the quality of every decision. Experience with your specific trial type, whether early-phase dose escalation or a large registrational study, matters greatly, as these demand very different capabilities. Biomarker and imaging capability is essential for modern precision-oncology trials. And a demonstrated recruitment track record in your indication is worth more than any promise, because enrollment is where oncology trials most often fail.
How to choose
Run a disciplined selection. Ask for specific, verifiable experience in your tumor type and trial design, not general oncology credentials. Probe hard on recruitment, asking how they will find your patients, which sites they will use, and what their track record is in comparable trials. Confirm who will actually staff your study and how senior they are. Assess whether their scale matches your needs, since a small biotech can get lost at a giant while a specialist may lack global reach. And weigh cultural fit and responsiveness, because oncology trials are long, complicated, and full of surprises, and you want a partner who communicates well when things go wrong.
The bottom line
The best CRO for an oncology trial is the one with genuine depth in your specific tumor type and trial design, real relationships with the sites that can enroll your patients, and the right scale for your program. The global players bring infrastructure and data; the oncology specialists bring concentrated expertise and site intimacy. Neither is universally better, but in a field where recruitment is the make-or-break challenge and the science is unforgiving, therapeutic depth and site access should weigh more heavily in your decision than brand or breadth.
Full-service or functional outsourcing?
A structural decision that shapes your oncology CRO relationship is whether to outsource the whole trial or only specific functions. In a full-service model, the CRO runs the study end to end, which suits sponsors without deep internal clinical operations capability and reduces the coordination burden, though it means ceding a good deal of control and depending heavily on the CRO’s execution. In a functional model, you retain overall control and contract out specific pieces, monitoring, data management, biostatistics, which suits sponsors with strong internal teams who want to keep strategic control and can manage multiple vendors. Many oncology sponsors, particularly small and mid-sized biotechs running their first significant trial, choose full service because they lack the internal infrastructure to do otherwise, and that is often the right call. But it makes the CRO choice even more consequential, because you are entrusting the entire execution of your most important program to them. If you go full service, insist on knowing exactly who will run your study, meet them, and assess their oncology experience directly rather than accepting the CRO’s institutional credentials. The team you get matters more than the logo, and in oncology, where operational judgment about enrollment, protocol deviations, and site management shapes outcomes daily, an experienced, engaged team at a mid-sized CRO frequently outperforms a junior team at a famous one. Ask the question directly, and be prepared to walk if the answer is unsatisfying.
Start the search early
A final practical point: begin your CRO search earlier than feels necessary. Selecting an oncology CRO properly, running a competitive process, checking references, meeting the actual team, and negotiating the contract, takes months, and rushing it because you are up against a deadline is how sponsors end up with the wrong partner. Building in adequate time also gives you leverage in the negotiation, since a CRO that knows you have no alternative has little reason to move on terms. Start the process well ahead of when you need the trial to begin, and you will make a better choice under far less pressure.
Recruitment is the question that matters most
If you take one thing from this, make it the recruitment conversation. Ask every candidate CRO exactly how they will find your patients: which sites, what their historical enrollment has been in comparable trials, how they will compete against the other studies chasing the same population, and what happens if enrollment falls behind plan. Push past reassurance to specifics, because vague confidence here is the leading indicator of a trial that stalls. The CRO that gives you a concrete, credible, slightly uncomfortable answer about the difficulty of recruitment is almost always the one that will actually deliver it.
Check the references properly
Before signing, speak to sponsors who have run oncology trials with the CRO you are considering, and ask specifically about enrollment performance against plan, the quality and stability of the team, and how the CRO behaved when problems arose. Ask whether they would use them again. These conversations routinely surface the issues that proposals conceal, and sponsors are usually candid with one another. Skipping this step to save a week is a false economy, given that you are about to entrust your most important program to the organization in question.
For the full, maintained list of contract research organizations, filterable by therapeutic focus, browse the BioMed Nexus CRO directory, and see our guides on how to choose a CRO and the phases of clinical trials.
Frequently asked questions
What are the best CROs for oncology trials?
The global full-service CROs with deep oncology franchises include IQVIA (notable for data assets that aid patient identification), Parexel, ICON, Fortrea, Thermo Fisher's PPD, and Medpace, which is often favored by small and mid-sized biotechs. Dedicated oncology-focused specialist CROs are frequently a better fit for early-phase or highly specialized cancer trials.
What makes oncology trials harder to run?
Patient recruitment is a persistent bottleneck because eligible patients are often defined by specific biomarkers or prior therapy lines and many trials compete for the same small pool. Trial designs are complex (adaptive, basket, umbrella, dose escalation), endpoints and imaging need specialized handling, leading cancer centers are selective and oversubscribed, and the science moves very fast.
How do I choose an oncology CRO?
Prioritize site relationships and access to the cancer centers that can enroll your patients, since recruitment is where oncology trials most often fail. Look for genuine therapeutic depth in your tumor type, experience with your specific trial design, biomarker and imaging capability, and a demonstrated recruitment track record in your indication rather than general oncology credentials.
